Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer
Authors
Keywords
-
Journal
TheScientificWorldJOURNAL
Volume 2014, Issue -, Pages 1-9
Publisher
Hindawi Limited
Online
2014-01-13
DOI
10.1155/2014/709736
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS
- (2013) Takashi Yoshioka et al. GYNECOLOGIC ONCOLOGY
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
- (2012) Ivan Diaz-Padilla et al. CANCER TREATMENT REVIEWS
- Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
- (2012) Keiko Shoji et al. PLoS One
- Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)
- (2011) C. Kollmannsberger et al. ANNALS OF ONCOLOGY
- PIK3R1 (p85 ) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
- (2011) M. E. Urick et al. CANCER RESEARCH
- Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
- (2011) C. Santiskulvong et al. CLINICAL CANCER RESEARCH
- The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
- (2011) H. Tanaka et al. CLINICAL CANCER RESEARCH
- A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas
- (2011) Meghan L. Rudd et al. CLINICAL CANCER RESEARCH
- Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
- (2011) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
- (2011) Catherine Delbaldo et al. Targeted Oncology
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
- (2010) Brian M. Slomovitz et al. CANCER
- Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy
- (2010) Andrew Y. Choo et al. CELL CYCLE
- A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies
- (2010) Sarah M. Temkin et al. GYNECOLOGIC ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
- (2010) P M Bhende et al. LEUKEMIA
- Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
- (2009) A. M. Roccaro et al. BLOOD
- The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
- (2009) K Shoji et al. BRITISH JOURNAL OF CANCER
- Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
- (2009) M Campone et al. BRITISH JOURNAL OF CANCER
- Synergistic effect of rapamycin and cisplatin in endometrial cancer cells
- (2009) Victoria L. Bae-Jump et al. CANCER
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
- (2009) Bijay S. Jaiswal et al. CANCER CELL
- Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235
- (2009) D. W. McMillin et al. CANCER RESEARCH
- Enhancing mTOR-targeted cancer therapy
- (2009) Xuerong Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma
- (2009) Monica Prasad Hayes et al. GYNECOLOGIC ONCOLOGY
- Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
- (2009) Aaron Shafer et al. INTERNATIONAL JOURNAL OF CANCER
- Utility of PTEN Expression of Endometrial “Surface Epithelial Changes” and Underlying Atypical Endometrial Hyperplasia
- (2009) M. Ruhul Quddus et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
- (2009) R. Marone et al. MOLECULAR CANCER RESEARCH
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
- (2009) T.-J. Liu et al. MOLECULAR CANCER THERAPEUTICS
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation
- (2008) X. Wang et al. CANCER RESEARCH
- PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation
- (2008) K. Oda et al. CANCER RESEARCH
- PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel
- (2008) L. Yang et al. CLINICAL CANCER RESEARCH
- Loss of Tuberous Sclerosis Complex-2 Function and Activation of Mammalian Target of Rapamycin Signaling in Endometrial Carcinoma
- (2008) K. H. Lu et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
- (2008) J LOPICCOLO et al. DRUG RESISTANCE UPDATES
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Mutual exclusiveness betweenPIK3CAandKRASmutations in endometrial carcinoma
- (2008) S. KANG et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro
- (2008) Silvia Darb-Esfahani et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- mTOR: The Mammalian Target of Replication
- (2008) Ezra E.W. Cohen JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Novel molecular profiles of endometrial cancer—new light through old windows
- (2007) A. Doll et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started